Enzolytics Inc. Releases 2024 Annual Report
Enzolytics Inc. has released its 2024 Annual Report, revealing total current assets of $200,005,177, down from $360,014,682 the previous year. The report highlights a significant business combination with Sagaliam Acquisition Corp., leading to the sale of its subsidiaries, Virogenetics, Inc. and Biogenysis, Inc., for $450 million. Following this, Biogenysis, Inc. was returned to Enzolytics, while Virogenetics, Inc. was exchanged for 20 million shares of Sagaliam Acquisition Corp.
Enzolytics Inc. has released its annual report for the year ending December 31, 2024. The company reported total current assets of $200,005,177, a decrease from $360,014,682 in the previous year. Notably, Enzolytics executed a significant business combination agreement with Sagaliam Acquisition Corp., resulting in the sale of its operating subsidiaries, Virogenetics, Inc. and Biogenysis, Inc., in a stock transaction valued at $450 million. Subsequently, a novation agreement returned the ownership of Biogenysis, Inc. to Enzolytics, while Virogenetics, Inc. was exchanged for 20,000,000 shares of Sagaliam Acquisition Corp. The full report can be accessed through the link below.
